#IMRN

1 week ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's release of first-half fiscal year 2026

#IMRN Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

www.stocktitan.net/news/IMRN/emerging-growt...

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference Immuron (NASDAQ: IMRN) CEO Steven Lydeamore will present virtually at the Coffee Microcaps Conference on 5 March 2026 from 11:00–11:30am Australian Eastern Time. A slide deck is available on the company investor website and the presentation is scheduled as a 30-minute virtual session.

#IMRN Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

www.stocktitan.net/news/IMRN/immuron-ceo-st...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target Immuron (Nasdaq:IMRN) reported first-half fiscal 2026 revenue of AUD$4.2 million for the six months ended December 31, 2025, a 5% increase year-over-year driven by Travelan sales in Australia and the U.S. Australian revenue rose 13% to AUD$3.3 million and U.S. revenue rose 17% to AUD$0.9 million; Canadian revenue declined due to distributor inventory dynamics.The firm launched ProIBS in December 2025 in Australia and continues to invest in its polyclonal antibody platform and clinical-stage pipeline. Emerging Growth Research maintained a Buy-Extended rating and a $3.50 12-month price target, citing current product revenue, early commercial traction, and clinical potential while noting reliance on external capital to fund development.

#IMRN Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

www.stocktitan.net/news/IMRN/emerging-growt...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Immuron Reports Continued Sales Growth Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative period (pcp) Q2 sales AUD$1.7 million up 11% on prior quarter Australian launch of

#IMRN Immuron Reports Continued Sales Growth

www.stocktitan.net/news/IMRN/immuron-report...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Wed Dec 3rd - #ARTL #DEVS #IMRN #LOT #WOK #VS #SONN #POLE #OMDA #IPWR #HCMA #CLNN #BWIN #ACHC #ADCT - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Immuron New U.S. Department of Defense Award & Clinical Trial Update Immuron (NASDAQ: IMRN) announced a U.S. Department of Defense-funded research award to develop two oral therapeutics targeting Campylobacter jejuni and Shigella sonnei.Under a collaboration with military research institutes and the Henry M. Jackson Foundation, new vaccine preparations were formulated and provided to Immuron, which will produce two hyper-immune bovine colostrum products for pre-clinical evaluation aimed at a combined colostrum-based therapeutic for U.S. military use.The company said topline results from the Uniformed Services University P2TD clinical trial (NCT04605783) of IMM-124E (Travelan active ingredient) are expected to be announced at the end of next week.

#IMRN Immuron New U.S. Department of Defense Award & Clinical Trial Update

www.stocktitan.net/news/IMRN/immuron-new-u-...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Immuron IMM-529 IND approved by FDA Immuron (NASDAQ:IMRN) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application for IMM-529 (IND 032095), enabling a Phase 2 randomized, double-blind, placebo-controlled trial in CDI patients to proceed.The study will enroll up to 60 subjects in a 2:1 IMM-529+SOC versus placebo+SOC design across multiple Australian sites, with first-half 2026 start planned. Primary objectives are safety and tolerability; efficacy will be measured by mortality, symptom scores and recurrence.Immuron cites preclinical results (prevention 80%; recurrence protection 67%; treatment 78.6%) and projects a base-case yearly revenue of US$400M if positioned at first recurrence, noting anticipated payer restrictions and oral dosing as a favorable attribute.

#IMRN Immuron IMM-529 IND approved by FDA

www.stocktitan.net/news/IMRN/immuron-imm-52...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Immuron Announces Clinical Trial Update Immuron (NASDAQ: IMRN) provided a clinical update on IMM-529 and Travelan on Oct 31, 2025. The company said its IMM-529 IND for Clostridioides difficile has been acknowledged by FDA CBER with an assigned biologic name and IND number, and is under active review after an Oct 25, 2025 FDA request for additional clinical information. Immuron submitted a comprehensive reply and made minor protocol updates ahead of the 30-day decision date.The Uniformed Services University Travelan P2TD study (n=851) topline results were delayed from end-Oct to end-Nov 2025 due to a U.S. government shutdown; those results will inform End-of-Phase 2 dosing (twice-daily vs three-times-daily).

#IMRN Immuron Announces Clinical Trial Update

www.stocktitan.net/news/IMRN/immuron-announ...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Immuron Q1 FY26 YoY growth Immuron (NASDAQ: IMRN) reported unaudited Q1 FY26 sales of AUD$2.0 million, up 34% year-over-year. Regional results show Australia AUD$1.6M (+52% YoY), USA AUD$0.4M (+44% YoY) and Canada AUD$0.0M (down 92% YoY).Management attributes growth to increased digital and social media marketing, same-store promotion effects, new retail listings in FY25 and higher South East Asian travel; U.S. growth was supported by an improved Amazon store, local social channels and paid/influencer campaigns. Canada had a large FY25 pipeline fill into over 1,000 retail doors and sales are expected to recover with seasonal travel and promotional activity later in the calendar year.

#IMRN Immuron Q1 FY26 YoY growth

www.stocktitan.net/news/IMRN/immuron-q1-fy2...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Immuron Submits IMM-529 IND to FDA Immuron (NASDAQ: IMRN) submitted an IND to the FDA for clinical development of IMM-529 to treat Clostridioides difficile infection (CDI) and prevent recurrent CDI (rCDI). The company plans to initiate a Phase 2 trial in H1 2026 enrolling first-episode and recurrent CDI patients. An independent market analysis estimates an eligible population of ~98,000 patients at first recurrence and a base-case annual revenue potential of ~US$400M pending efficacy. IMM-529 is an oral, three-target polyclonal antibody candidate directed at Toxin B, spores, and surface layer proteins, with preclinical results reporting prevention of primary disease (80% P=0.0052), protection of recurrence (67% P<0.01) and treatment of primary disease (78.6% P<0.0001).

#IMRN Immuron Submits IMM-529 IND to FDA

www.stocktitan.net/news/IMRN/immuron-submit...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Trade Alerts, Thursday October 2, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Thu Oct 2nd - #IMRN #TSAS #SHLS #NVTS #MNPR #GIFI #DFLI #CAN #BTTC #CIGL #ANGX - More: crystalequityresearch.com/trade-alerts... - #smallcap